Cicor's Record Growth Driven by Strategic Expansion

Cicor Technologies Ltd has reported record sales and profits for 2024, largely due to strategic expansion efforts. The company achieved significant gains in market share, with sales increasing by 23.3% to CHF 480.8 million despite a 14% drop in the European EMS market. Acquisitions played a key role, contributing 26.1% to sales growth. Earnings per share climbed to CHF 6.20, with free cash flow of CHF 6.3 million post-acquisitions.

The EBITDA margin rose to 12.1%, and net profit surged by 131.7% to CHF 27.3 million. Cicor's focus on medical technology, aerospace, defence, and industrial applications drove growth, with aerospace and defence expanding by 94.4%. The year-end order backlog was stable, with improved profit margins across divisions.

In 2025, Cicor anticipates further sales growth, bolstered by recent acquisitions. The company aims for sales over CHF 1 billion by 2028, underscoring its strategy to be a leading partner in electronic design and manufacturing.